Bixiye
bc-mhcp-pharmprogpolicynotifctn-eff-9-1-24.pdf
Natiijooyinka Raadinta
Soo bandhiga 1181 - 1190 ee natiijooyinka 5055
Bixiye
P57-24 MagellanRx Management, a Prime Therapeutics Company (UM) Program: Medical Drug Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
QP68-24 MHCP Pharmacy Benefit Exclusion for Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP67-24 Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP65-24 PCA Agency Requirements
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP66-24 Reminder: Patient Complaint Policy and Process Requirements
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP62-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective October 1, 2024
Taariikhda barnaamijka Dhaqangalayso Agosto 14, 2024
Sheegashooyinka iyo Racfaanada
Faa'iidooyinka & Caymiska
Blue Plus Member Authorization form
Bixiye
QP64-24 MHCP Pharmacy Benefit Exclusion for Rytelo™
Taariikhda barnaamijka Dhaqangalayso Agosto 14, 2024
Bixiye
QP63-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2024
Taariikhda barnaamijka Dhaqangalayso Agosto 14, 2024